Local therapy with an engineered oncolytic adenovirus enables antitumor response in non- injected melanoma tumors in mice treated with aPD-1

Dafne C. A. Quixabeira, Victor Cervera-Carrascon, Joao M. Santos, James H. A. Clubb, Tatiana V. Kudling, Saru Basnet, Camilla Heiniö, Susanna Grönberg-Vähä-Koskela, Marjukka Anttila, Riikka Havunen, Anna Kanerva, Akseli Hemminki

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
Article number2028960
JournalOncoImmunology
Volume11
Issue number1
Number of pages14
ISSN2162-4011
DOIs
Publication statusPublished - 22 Jan 2022
MoE publication typeA1 Journal article-refereed

Fields of Science

  • DELIVERY
  • IL-2
  • INNATE IMMUNITY
  • NECROSIS-FACTOR-ALPHA
  • Oncolytic adenovirus
  • PROMOTES
  • RESISTANCE
  • SURVIVAL
  • T-CELL IMMUNITY
  • TNFa
  • aPD-1
  • immunotherapy
  • lymphocytes
  • melanoma
  • 3122 Cancers
  • 3111 Biomedicine

Cite this